Morosini Deborah
Known title: EVP, Chief of Clinical AffairsCIK: 0001824625
Associated companies
Transaction History
| PRLD | ▲ Buy | Option Exercise | 3,016 | $6K | 12/15/2021 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 25,735 | $331K | 12/15/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 28,751 | $374K | 12/15/2021 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 28,751 | $369K | 11/16/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 28,351 | $450K | 11/16/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 400 | $7K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.